Xinkanghe Biomedicine

Xinkanghe Biomedicine is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, focused on developing innovative small molecule drugs for autoimmune and inflammatory diseases. The company's research and development efforts center on highly selective kinase inhibitors, aiming to improve the safety and efficacy profiles of existing treatments. Its lead program, XKH001, is a selective Janus kinase 1 (JAK1) inhibitor in Phase 2 clinical development for atopic dermatitis and other immune-mediated conditions. Additionally, Xinkanghe is advancing XKH002, a Tyrosine kinase 2 (TYK2) inhibitor, targeting psoriasis and related inflammatory disorders. By leveraging its expertise in medicinal chemistry, the company seeks to address significant unmet medical needs in the global immunology market.